Drugs that target mitotic spindle proteins have been proven useful for tackling tumour growth. Eg5, a kinesin-5 family member, represents a potential target since its inhibition leads to prolonged mitotic arrest through the activation of the mitotic checkpoint and apoptotic cell death. Monastrol, a specific dihydropyrimidine (DHPM) inhibitor of Eg5, shows stereospecificity, since predominantly the (S)-, but not the (R)-enantiomer has been shown to be the biologically active compound in vitro and in cell-based assays. Here, we solved the crystal structure (2.7 Å) of the complex between human Eg5 and a new keto derivative of monastrol (named mon-97), a potent antimitotic inhibitor. Surprisingly, we identified the (R)-enantiomer bound in the active site, and not, as for monastrol, the (S)-enantiomer. The absolute configuration of this more active (R)-enantiomer has been unambiguously determined via chemical correlation and X-ray analysis.
Drugs that target mitotic spindle proteins have been proven useful for tackling tumour growth. Eg5, a kinesin-5 family member, represents a potential target since its inhibition leads to prolonged mitotic arrest through the activation of the mitotic checkpoint and apoptotic cell death. Monastrol, a specific dihydropyrimidine (DHPM) inhibitor of Eg5, shows stereospecificity, since predominantly the (S)-, but not the (R)-enantiomer has been shown to be the biologically active compound in vitro and in cell-based assays. Here, we solved the crystal structure (2.7 Å) of the complex between human Eg5 and a new keto derivative of monastrol (named mon-97), a potent antimitotic inhibitor. Surprisingly, we identified the (R)-enantiomer bound in the active site, and not, as for monastrol, the (S)-enantiomer. The absolute configuration of this more active (R)-enantiomer has been unambiguously determined via chemical correlation and X-ray analysis.
Unexpectedly, both the (R)-and the (S)-forms inhibit Eg5
ATPase activity with IC 50 values of 110 nM and 520 nM (basal assays) and 150 nM and 650 nM (MT-stimulated assays), respectively. However, the difference was large enough for the protein to select the (R)-over the (S)-enantiomer. Taken together, these results show that in this new monastrol family, both (R)-and (S)-enantiomers can be active as Eg5 inhibitors. This considerably broadens the alternatives for rational drug design.
The mitotic spindle is a recognized target in cancer chemotherapy to inhibit cell proliferation by blocking microtubules (MTs).
Nowadays some proteins of several other superfamilies, also associated to the spindle, have moved to the spotlight, including kinases like the Auroras (1) and Polo (2) , or Eg5, a member of the kinesin superfamily that belongs to the kinesin-5 family (3). Several structurally unrelated chemical compounds have been identified (4) that inhibit Eg5 in vitro by locking the motor in a conformation that cannot release ADP from the active site (5-7). In cell-based assays this results in a failure of cells to separate the duplicated centrosomes (8) leading to mitotic arrest and eventually apoptotic cell death (9) (10) (11) . Monastrol (figure 1A), the first Eg5 inhibitor identified (8) , serves as a model to understand the mechanism in molecular detail of how a motor is inhibited (5) (6) (7) (12) (13) (14) (15) (16) . This small molecule is used for "chemical genetics" to understand the function of Eg5 or to reveal basic questions of cell division (17) , but also serves as a basis for the development of more potent monastrol-based drugs (18) that might be of therapeutic value for cancer chemotherapy in the future. In cell-based assays the effect of racemic monastrol is rather weak with an IC 50 of roughly 50-60 µM (5,6,9), but has been improved by chemical optimization (18) . There is stereo-selectivity since the (S)-enantiomer of monastrol binds preferentially to Eg5 (5,6) whereas the (R)-enantiomer shows significantly reduced inhibitory activity. The crystal structures of the Eg5 motor domain alone (19) and in complex with (S)-monastrol (20) have been solved allowing a detailed atomic analysis of the interactions that occur in the inhibitor binding pocket and reflected an important advancement in the elucidation of the inhibition mechanism.
In addition, the crystal structure allows rational design of new monastrol analogues that might result in improved effectiveness of the inhibitor compared to the original compound. There are several good reasons to further develop more potent monastrol-based compounds as drug candidates. First, the parallel synthesis of new analogues using combinatorial chemistry is easily accessible through the one-pot Biginelli three-component cyclocondensation (21) . Second a highly enantioselective Biginelli asymmetric synthesis for dihydropyrimidines (DHPMs) is now available (22) allowing the enriched synthesis of one enantiomer over the other. We have recently prepared a library of about 140 monastrol analogues (DHPM core structure) using combinatorial chemistry techniques for Structure-Activity-Relationship (SAR) studies and tested their inhibition of Eg5 ATPase activity as well as induction of monoastral spindles in HeLa cells, which led to the identification of more potent monastrol analogues (23) (24) . Surprisingly, a subgroup of compounds effectively inhibited Eg5, although the inhibition could not be explained by modeling these compounds into the inhibitor binding pocket, based on the current model of the Eg5 -(S)-monastrol complex. The first likely possibility is that the structure of the inhibitor-binding pocket changes to better accommodate the inhibitor analogue. A second possibility is that the conformational change induced by the presence of a phenyl group in this new Eg5 inhibitor analogue imposes a different positioning with respect to monastrol to be accommodated by the Eg5 inhibitorbinding pocket. Here we report the crystal structure of human Eg5 in complex with a new monastrol analogue named (R)-mon-97, belonging to the new potent ketodihydropyrimidine family (figure 1B). We show that while monastrol binds to Eg5 as the (S)-enantiomer, it is the (R)-enantiomer of mon-97 that binds to the same site. Surprisingly the structure of the inhibitor binding pocket as well as the overall Eg5 structure is very similar to that of the Eg5 -(S)-monastrol complex. These results show that rational drug design of monastrol-type analogues that is only based on the structure of the Eg5 -(S)-monastrol complex should therefore be taken cautiously, since some important active analogues might simply be missed. Future work on developing more effective inhibitor analogues should certainly consider these results broadening the possibilities to find even more potent DHPMbased inhibitors.
Experimental procedures
Protein expression and purification. The motor domain of human Eg5 (residues 1-386) was initially cloned into the His tag vector pET28a, expressed in E. coli BL21(DE3)pLys (Novagen) and purified with a 5 ml HisTrap HP column using standard FPLC procedures (Amersham Biosciences). Failure to crystallize the His-tagged protein led us to modify the original vector by site-directed mutagenesis in order to shorten the protein construct to 368 residues (19) and to remove the expression of the Histidine tag by using the QuikChange Site-Directed Mutagenesis Kit (Stratagene) and the following forward and reverse primers: Eg5-1, 5'-CCT GAA GTG AAT CAG AAA TGA ACC AAA AAA GCT TTG ATT AAG G-3'; Eg5-2, 5'-C CTT AAT CAA AGC TTT TTT GGT TCA TTT CTG ATT CAC TTC AGG-3'. The modified plasmid was transformed into E. coli BL21(DE3)Star (Invitrogen). Further purification steps follow the protocol described by Turner et al. (19) with minor modifications. Three liters of bacterial culture were grown at 37°C in 2xYT medium to an A 600 nm of approx. 0.7, and induced overnight with 0.5 mM IPTG (MP Biomedicals). Harvested cells were suspended in 25 ml of buffer A (50 mM PIPES pH 6.8, 2 mM MgCl 2 , 1 mM ATP, 1 mM TCEP, 1 mM EGTA) supplemented with 1/2 tablet of a cocktail of protein inhibitors (Complete EDTA-free, Roche) and 2.5 mg of lysozyme and disrupted by four cycles of freeze-thaw. After bacterial lysis, 1 mM DNAse I and 10 mM MgCl 2 were added and incubated in gentle centrifugal mixing during 1 h at 4°C (all the following steps were performed at this temperature). The cell lysate was centrifuged at 40 000 rpm for 1 h and the supernatant was mixed with a pre-equilibrated ion-exchange cellulose DE-52 (Whatman) in buffer A (approx. 5 ml equilibrated resin for 6 ml of supernatant). Resin and sample were mixed gently for a few min, loaded onto a plastic syringe and the flow-through and 2 column washes were collected. The pooled sample was applied to a 5 ml SP-Sepharose HP column (Amersham Biosciences) previously equilibrated with buffer A. The protein was eluted by using a KCl gradient (buffer B: buffer A + 250 mM KCl) at approx. 140 mM. Eg5 fractions were identified by SDS-PAGE, pooled and diluted with buffer A to 50 mM KCl. The protein sample was loaded onto a pre-equilibrated 5 ml Q-Sepharose HP column (Amersham Biosciences) with buffer A, and fractions were collected immediately and analyzed by SDS-PAGE. Purified Eg5 (about 24 mg of protein) was concentrated to 10 mg/ml, frozen in liquid nitrogen and stored at -20°C.
Crystallization of the Eg5-(R)-mon97 complex.
Crystals obtained with mon-97 appeared after 5 days in hanging drops by mixing 1 µl protein (7.7 mg/ml), 1 µl reservoir containing 20% PEG4000, 0. and 8% erythritol, after 2 days using vapour diffusion by hanging drops (1 µl protein and 1 µl reservoir) in 24 well VDX plates at 20°C. The crystal tested was monoclinic P2 1 with unit cell parameters a = 52.36 Å, b = 77.76 Å, c = 93.06 Å and β = 93.76° and 2 molecules per asymmetric unit as previously described (19) .
Data collection, structure determination and refinement. The Eg5-mon-97 crystals were measured on beamline BM30A at the ESRF (European Synchrotron Radiation Facility, Grenoble, France). Data were processed at 2.7 Å with XDS and scaled with XSCALE (25) . Since this crystal had the same space group and similar unit cell parameters as the crystal structure of Eg5 in complex with (S)-monastrol (20; PDB: 1Q0B), this structure was used without inhibitor, Mg 2+ ADP or solvent molecules, as a model for rigid-body refinement using RIGID from CNS (26) . The refinement yielded a R free of 31.2%. An initial electron density map inspection showed the presence of Mg 2+ ADP in the nucleotidebinding site plus an extra density around loop L5 that indicated the presence of the inhibitor. The model was rebuilt manually using TURBO-FRODO (27) and refined by successive runs of density modification by solvent flipping, energy minimization and Bfactor refinement. Mg 2+ ADP was included in early stages of refinement and water molecules were added progressively. The (R)-mon-97 structure deduced from the X-ray data of the (R,R) corresponding diastereoisomer (vide infra) was fitted in the last steps of refinement into the electron density. The final R working and R free for the Eg5 -(R)-mon-97 model were 23.4% and 28.1%, respectively; more data collection and refinement statistics are shown in Table 1 . The quality of the final model was assessed with PROCHECK (28) and WHAT IF (29) by uploading the structure to the Biotech Validation Suite for Protein Structures server (http://biotech.ebi.ac.uk:8400/). The Ramachandran plot showed 90.3% of residues in most favoured regions and 9.7% in additional allowed regions. A data set of native Eg5 to 2.5 Å was collected on ID14-3 at the ESRF, to have an in-house reference model in case modifications in purification, etc. would occur and affect the Eg5 structure in comparison with the formerly published structure. We also wanted to be able to compare the electron densities of native and inhibitor-bound structures and not only rely on the structure coordinates. Data were processed with DENZO/SCALEPACK (30) and SCALA from CCP4 (31). The structure was solved by molecular replacement using AMoRe (32) and the subunit A of the native Eg5 structure (19; PDB: 1II6), as a model. A two molecule / asymmetric unit search, yielded a correlation coefficient of 60.8% and R-factor of 38.3%. Cycles of manual building using TURBO-FRODO (27) , energy minimization, B-factor refinement and automatic water molecule picking at latter stages of refinement using CNS (26) gave a final model with R working 23 .01% and R free 26.9%. After confirming that our in-house structure and 1II6 were almost identical, we used 1II6 for structural superpositions since this structure was reported to higher resolution (2.1 Å). Structural superpositions were calculated using the server SuperPose Version 1.0 (http://wishart.biology.ualberta.ca/superpose/) (33) .
Preparation of mon-97. Racemic mon-97 was prepared using a modification of the procedure by Dondoni and colleagues (34) . To a stirred solution of 3-hydroxybenzaldehyde (3.7 g, 30 mmol, 1.0 eq) we added benzoylacetone (4.9 g, 30 mmol, 1.0 eq ), methylthiourea (0.93 g, 90 mmol, 3.0 eq) and Ytterbium triflate (0.93 g, 1.5 mmol, 0.05 eq). The mixture was refluxed overnight and evaporated. Ethylacetate was added and the insoluble material was removed by filtration. The filtrate was washed with brine, dried over MgSO 4 and concentrated in vacuo. The crude solid obtained was crystallized from a ether:hexane mixture and yielded 4.25 g (42%) of mon-97 as a white solid.
Separation of mon-97 enantiomers by chiral HPLC.
The two enantiomers were separated by chiral high performance liquid chromatography (ChiralPack AS, 250 x 4.6 mm), elution hexane/ethanol, 86:14 v/v; flow rate, 1.0 ml/min, detection 220 nm.
Preparation of the Mosher ester. 2.4 g imidazole (34.7 mmol, 2.2 eq) and 2.6 g tertButyldimethylsilyl chloride (17.4 mmol, 1.1 eq) were added to a stirred solution of 5.35 g mon-97 (15.8 mmol, 1.0 eq) in 50 ml of dry DMF and stirred overnight at RT. The mixture was diluted with water and extracted with Et 2 O (4 x 50 ml). The combined organic phases were washed with a CuSO 4 solution (2 x 50 ml) followed by brine, dried over anhydrous MgSO 4 and evaporated under vacuum. Purification by crystallization with hexane:ether yielded 2.6 g (37%) of pure silylated aldehyde as a pale yellow solid. 164 mg (0.36 mmol) of this silylated compound in 2 ml CH 2 Cl 2 was added to a mixture of (R)-(+)-Mosher acid (127 mg, 0.54 mmol, dicyclohehylcarbodiimide (134 mg, 0.65 mmol) and dimethylaminopyridine (16 mg, 0.13 mmol)) in 4 ml of dry dichloromethane. The resulting mixture was stirred for 48 h at RT. The precipitate obtained by adding 25 ml diethylether was removed by filtration. The filtrate was washed successively with diluted aqueous HCl solution (2 x 10 ml), water (15 ml), aqueous saturated NaHCO 3 (2 x 10 ml), and finally brine. The organic layer was dried over MgSO 4 with SHELXL-97 (35) . Absorption effects were corrected with SCALEPACK (30). All non-hydrogen atoms were refined with anisotropic displacement parameters. The hydrogen atoms were introduced at calculated positions and were treated as riding atoms with an isotropic displacement parameter equal to 1.2 (CH) or 1.5 (CH 3 ) times that of the parent atom. Thanks to the presence of anomalous scatterers, the absolute configuration could be determined. 2788 Friedel pairs were measured and the correct enantiomorph was determined from the value of the Flack parameter, refined together with all other parameters, -0.10(8) (36) .
Crystal data and refinement details. 
Basal and MT-stimulated ATPase activity tests. The inhibition of basal and MT-stimulated Eg5
ATPase activity by (R)-and (S)-enantiomers of mon-97 was measured as described previously (6) .
Results

Structure of the protein-inhibitor complex. The crystal structure of Eg5 in complex with mon-97 (fig. 2) contains 2 molecules per asymmetric unit (named A and B). Each Eg5
molecule has one Mg 2+ ADP located in the nucleotide-binding site, one molecule of the inhibitor mon-97 and a total of 214 water molecules. We used racemic mon-97 for crystallization, expecting to identify, as in the case of monastrol, the (S)-enantiomer in the inhibitor-binding pocket. However, our first attempts to fit a generated (S)-mon-97 form into the electron density map failed and we decided to build mon-97 without any constraints and assumptions into the density ( fig. 1 supplementary material) . We constructed an inhibitor conformation that nicely fitted into the electron density. After applying the Cahn-Ingold-Prelog system to unambiguously determine the absolute configuration of bound mon-97, we found to our surprise that the (R)-, but not the (S)-enantiomer was present in the crystal structure. (R)-mon-97 is located in a cavity delimited by loop L5, α2, α3 and β4 ( fig. 2) . The residues that are in direct contact with the inhibitor are: Glu116, Gly117, Glu118, Arg119, Trp127 and Ala133 (loop L5), Leu160 (strand β4) and Tyr211, Glu215 and Arg221 (helix α3). There are slight differences between the inhibitor found in the two molecules of the asymmetric unit: in molecule A there are additional hydrophobic contacts with Pro137 (helix α2), Leu214 and Ala218 (helix α3) (distance < 3.9 Å) ( fig. 3A and fig. 4A 5B ). The (R,R)-diastereoisomer was then deprotected to enantiopure (R)-mon-97, the retention time of which was shown by chiral HPLC to be identical to the more active Eg5 inhibitor obtained from racemic mon-97 i.e. the (R)-enantiomer of mon-97. Eg5 inhibition was also higher for this "chemically-resolved" enantiomer (data not shown). This result also showed that (R)-mon-97 alone and in complex with Eg5 has almost identical conformations.
Inhibition of basal and MT-stimulated Eg5
ATPase activities. Subsequently, we measured the inhibition of the basal and MT-stimulated Eg5 ATPase activity. In both cases the (R)-enantiomer of mon-97 is the more active agent with IC 50 values of 110 nM (basal) and 150 nM (MT-stimulated) compared to 520 nM (basal) and 650 nM (MT-stimulated) for the (S)-enantiomer ( fig. 6 ). That is in contrast with the reported activity for monastrol, where predominantly the (S)-enantiomer shows good inhibition properties.
Discussion
Diverse biological roles of dihydropyrimidines. DHPMs represent a surprisingly diverse family of biologically active compounds (21) . They are known to act as calcium channel modulators for the treatment of cardiovascular diseases, as potential α 1a adrenoceptor-selective antagonists used to relieve the symptoms of benign prostatic hyperplasia (BPH), and as inhibitors of the kinesin superfamily member Eg5, becoming potential lead compounds for drug development in cancer chemotherapy. The crystal structure of the Eg5 -(S)-monastrol complex was the first structure of a DHPM in complex with its protein target (20) . Our new structure of Eg5, in complex with a new, more potent monastrol analogue in its (R)-configuration provides novel insights into the biochemical mechanism of inhibition of Eg5 by antimitotic agents.
Structural comparison between (S)-monastrol and (R)-mon-97 complexes.
Structural comparison between Eg5 -(R)-mon-97 and the complex with (S)-monastrol shows almost identical overall conformational modifications to Eg5 compared to the native structure. This strongly suggests that they have a similar mode of action. In addition both compounds bind in the same pocket formed by loop L5/α2 and α3. Therefore, minor differences in the inhibitor binding pocket must be responsible for the enormous differences in affinities for the two compounds: (S)-monastrol inhibits the basal Eg5 ATPase activity with an IC 50 value of 1.7 µM, whereas (R)-monastrol displays an IC 50 value of about 8.2 µM (data not shown). (R)-mon-97 and (S)-mon-97 have IC 50 values of 110 nM and 520 nM, respectively, which is about 17 times better. The improved affinity can be explained by the different binding modes of the two DHPM inhibitors. Overall, the complex with (R)-mon-97 shows more hydrophobic contacts with residues of loop L5/α2 and α3 ( fig. 4A ). In the Eg5 -(S)-monastrol complex, the ethylester group point towards the solvent and makes contact with a water molecule (fig. 3B, fig. 4B ). In contrast, the phenyl group in (R)-mon-97, that substitutes the ethyl group in (S)-monastrol, fits nicely in the hydrophobic pocket filling the cavity by exerting hydrophobic interactions with residues Glu116, Leu160, Leu214, Glu215, Arg221, (fig. 3A, fig. 4A, fig. 7A ), while in the complex with (S)-monastrol this cavity remains empty (figure 7B). It is noteworthy that Gly117 (loop L5), Leu160, located in strand β4, Glu215 and Arg221 (α3) do not interact in the complex with (S)-monastrol. In contrast (R)-mon-97 does not contact Ile136 that is involved in binding of the sulfur atom in the (S)-monastrol complex. In the (R)-mon-97 complex it is Glu118 that contacts the sulfur atom and there is no water molecule implicated.
Comparison with other Eg5 -inhibitor complexes. Structural comparisons of Eg5 -(R)-mon-97 have been performed with native Eg5 (PDB: 1II6) and Eg5 in complex with structurally different inhibitors found to date in the PDB: (S)-monastrol (PDB: 1Q0B), two 3,5-diaryl-4,5-dihydropyrazole analogues (PDB: 1YRS and 2G1Q), three 2,4-diaryl-2,5-dihydropyrrole analogues (PDB: 2FKY, 2FL2, 2FL6), a 4-phenyl-tetrahydroisoquinoline analogue (PDB: 2FME), and a pyrrolotriazine-4-one analogue (PDB: 2GM1) (19, 20, (38) (39) (40) (41) (42) . Structural differences between native Eg5 and complexed with (S)-monastrol have been identified previously (20) . These mainly concern loop L5, the switch I and switch II region and the neck linker. The distal differences are conserved throughout all Eg5 -inhibitor complexes without exception: switch I, which is a featureless loop in the binary Eg5 -ADP complex turns into a short helix in the ternary Eg5 -ADP -inhibitor complex and the helix α4 displays a 20° wider opening (switch II helix up), when compared to native Eg5. It is also noteworthy that in our inhibitor-bound structure the onset of switch helix α4 is two turns shorter than in native Eg5. Interestingly it has been shown for Kif1A that the length of this helix depends on the nucleotide state (43) . In all cases, the neck-linker shows a rotation of about 120° and is in a docked conformation (movie 1 suppl. material). In the Eg5-ADPmon-97 structure, Eg5 appears to simulate an ATP-like state as previously shown for the complex with (S)-monastrol. Proximal structural changes in the inhibitorbinding pocket of Eg5 are as conserved as the distal changes: all inhibitors bind to the same pocket formed by loop L5/α2 and α3. With the unique exception of Eg5 in complex with the bulkier pyrrolotriazine-4-one analogue, all inhibitors bind by forming a structurally very similar binding pocket. The differences observed in comparison with 2GM1 (overall main-chain r.m.s.d. 1.24 Å and 0.96 Å for the loop L5 area), where the bulky pyrrolotriazine analogue causes considerable changes in the induced fit conformation of loop L5, indicate that this loop is also capable of adapting to different inhibitor compound conformations. There are also noteworthy proximal similarities in the inhibitor-binding pocket formed by the two adjacent elements, loop L5/α2 and α3. All inhibitors, for which structural information is available, interact systematically with both adjacent secondary structure elements, never with one alone. The conserved residues involved in inhibitor binding in all the structures analyzed: Glu116, Glu118, Arg119 and Pro137 (L5/α2) and Leu 214 (α3) are located in these areas. As already shown for the (R)-mon-97 complex, residue Leu160 of strand β4 is also implicated in the interaction in almost all Eg5-inhibitor complexes except for 2FME and the structure obtained with (S)-monastrol (PDB: 1Q0B). In conclusion, we observed that despite the type of inhibitor, the allosteric pocket re-arranges around the different classes of inhibitors in a very similar manner (with the exception of the bulky pyrrolotriazine derivative).
Implications for rational drug design. Rational drug design uses the knowledge gained from structural information of protein-inhibitor complexes to develop improved and more effective inhibitor analogues. The fact that the (S)-enantiomer of monastrol and the (R)-enantiomer of the similar mon-97 analogue is selected by the enzyme for complex formation leading to different binding modes, and the slightly different conformations of (R)-mon-97 found in the two Eg5 molecules of the asymmetric unit, are indicative of the compounds flexibility and shows the difficulty of any in silico drug design prediction for this type of molecules. For the development of more potent lead compounds by rational drug design based on the DHPM scaffold it will be necessary to take into account the possibility that for certain analogues either the (R)-or the (S)-enantiomer or both can bind to the inhibitor-binding pocket as we have shown for this N-methyl ketoderivative DHPM, mon-97. Although it complicates the drug design task it offers the chance of finding more potentially effective DHPM inhibitors for Eg5 in the future. Figures 2, 3 , 5B and 7 were generated using PyMOL (44) . (45) . Hydrophobic contacts (< 3.9 Å) and hydrogen bonds are depicted with red and green dashed lines, respectively. The ethyl group of (S)-monastrol points toward the solvent, whereas in the (R)-mon-97 structure the phenyl group that substitutes the ethyl group is buried in the hydrophobic pocket. c R sym = ∑I j -< I > / ∑ < I >, where I j is the intensity for reflection j, and < I > is the mean intensity.
d R working = ∑F o -F c / ∑F c , calculated with the working set.
e R free was similarly calculated with 5% of the data excluded from the calculation of R working . 
